Envision Pharma Group
unveils new agency structure

Envision Pharma Group has unveiled a new agency structure for its medical communications business, bringing its legacy agency divisions together under a “simpler, more customer-centric” framework.

The introduction of Envision 90TEN, Envision Catalyst, Envision Ignite and Envision Spark is aimed at complementing Envision Pharma Group’s “broader investments” in artificial intelligence, market access and technology platforms, the company said.

It added that the agencies will “continue to offer bespoke solutions built around their clients’ requirements” and “remain deeply connected” with Envision’s broader goal of changing how life sciences companies communicate scientific and medical value through the integration of advanced technology, real-world evidence and people-centred strategy.

Alice Choi, president of Envision Medical Communications, said: “With the introduction of Envision 90TEN, Envision Catalyst, Envision Ignite and Envision Spark, we’ve built a model around what our clients value most: teams who challenge them to innovate; meaningful scientific communication; and a partner who listens and evolves with them.”

Together, the four newly appointed global agency heads: Kathryn Gray; Liz Boden; Kirsten Parr and Kristyn Morgan, have decades of experience across healthcare communications, technology integration, medical affairs and brand strategy.

Kristyn Morgan, head of Envision Spark, has held positions of increasing responsibility over more than 18 years at Envision Pharma Group, after beginning her career at Medknowledge Group and Pharmedica. Kathryn Gray, head of Envision 90TEN, has held senior roles at Envision for almost four years, having previously held a range of positions at Alligent Group, Gardiner-Caldwell Communications and MediTech Media.

Liz Boden, head of Envision Catalyst, and Kirsten Parr, head of Envision Ignite, are both relatively new to Envision Pharma Group. Boden previously served in roles at Bioscript Group, SCIRIS, McCann Health Medical Communications and Ashfield, while Parr has held positions at CMC Connect, Complete Medical Communications, Fishawack Health and Gardiner-Caldwell Communications.

“These agencies reflect our belief that the future of medical communications lies in strategic thinking that is both nimble and customised, leveraging technology to build on the strength of science,” Choi said. “Our agency heads bring a human-centred leadership philosophy that reflects our commitment to both client success and patient outcomes.”

The announcement came less than four months after Envision launched EnvisionOne Vantage, a solution allowing medical affairs professionals to benchmark their publication performance against other pharmaceutical companies.

EnvisionOne Vantage, the second solution for the company’s EnvisionOne data platform, has been designed to help uncover factors that may influence submission rates or acceptance times, and highlight areas for improvement.